Sugi Predict

Sugi Predict / Compounds / SCHEMBL1495735

SCHEMBL1495735

SCHEMBL1495735

COC(=O)c1cc(Br)cc(CO)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.54
▸ PRKCA P17252 2/20 0.46
▸ PRKCD Q05655 2/20 0.46
▸ CYP4A11 Q02928 4/20 0.46
▸ CYP4F2 P78329 3/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ CA14 Q9ULX7 1/20 0.46
▸ SLC7A5 Q01650 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ LMNA P02545 3/20 0.44
▸ POLB P06746 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ XDH P47989 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546155 1.00 NOTUM (0.54) NOTUMPRKCAPRKCDCYP4A11CYP4F2
SCHEMBL2228104 0.89 NOTUM (0.57) NOTUMCYP4A11CYP4F2CA12CA1
SCHEMBL16010428 0.88 NOTUM (0.53) NOTUMCYP4A11CYP4F2CA12CA1
SCHEMBL2650418 0.87 CA12 (0.54) PRKCAPRKCDCYP4A11CYP4F2CA12
SCHEMBL762861 0.87 CA12 (0.54) PRKCAPRKCDCYP4A11CYP4F2CA12
SCHEMBL17115914 0.86 CYP4A11 (0.59) NOTUMCYP4A11CYP4F2CA12CA1
SCHEMBL3602876 0.86 NOTUM (0.54) NOTUMCYP4A11CYP4F2CA12CA1
SCHEMBL16951249 0.85 PRKCA (0.49) NOTUMPRKCAPRKCDCYP4A11CYP4F2
SCHEMBL16533838 0.84 NOTUM (0.53) NOTUMCYP4A11CYP4F2CA12CA1
SCHEMBL16098497 0.84 CA12 (0.53) PRKCAPRKCDCYP4A11CYP4F2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108482-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS ESCIENT PHARMACEUTICALS INC (US) 2026-04-23 — — US disclosed
WO-2025001407-A1 POLYARYL-CONTAINING MACROCYCLIC COMPOUNDS AND USES THEREOF 浙江养生堂天然药物研究所有限公司 2025-01-02 — — WO disclosed
CN-119192199-A Polyaryl-containing macrocyclic compounds and uses thereof 浙江养生堂天然药物研究所有限公司 2024-12-27 — — CN disclosed
US-20240300907-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2024-09-12 — — US disclosed
EP-4400172-A2 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS Incyte Holdings Corporation (US) 2024-07-17 — — EP disclosed
EP-4036088-B1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE HOLDINGS CORP (US) 2024-04-03 — — EP disclosed
US-11840521-B2 Modulators of Mas-related G-protein receptor X4 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2023-12-12 — — US disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
US-20230159474-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2023-05-25 — — US disclosed
US-6949668-B2 Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound TEIJIN LIMITED (JP) 2005-09-27 — — US disclosed
CN-1582272-A Process for preparing 5- (3-cyanophenyl) -3-formylbenzoic acid compounds TEIJIN LTD (JP) 2005-02-16 — — CN disclosed
US-20050014966-A1 Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound TEIJIN LIMITED (JP) 2005-01-20 — — US disclosed
EP-1460059-A1 PROCESS FOR PRODUCING 5-(3-CYANOPHENYL)-3-FORMYLBENZOIC ACID COMPOUND TEIJIN LIMITED (JP) 2004-09-22 — — EP disclosed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 — — EP disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 — — US disclosed
US-20030203935-A1 Cyanobiphenyl derivatives TEIJIN LIMITED 2003-10-30 — — US disclosed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 — — WO disclosed
US-6538137-B1 Blood-coagulation factor X inhibitors TEIJIN LIMITED (JP) 2003-03-25 — — US disclosed
EP-1179527-A1 CYANOBIPHENYL DERIVATIVES TEIJIN LIMITED (JP) 2002-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11840521-B2 Modulators of Mas-related G-protein receptor X4 and related products and methods MRGPRX4, MRGPRX1, MRGPRX2 NOTUM 4318/4885PRKCA 2409/4885PRKCD 2383/4885
US-20050014966-A1 Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound PAH, CA5B, PCCA NOTUM 3525/4885PRKCA 3214/4885PRKCD 3794/4885
US-20260108482-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS MRGPRX4, MRGPRX1, MRGPRX2 NOTUM 4535/4885PRKCA 1431/4885PRKCD 988/4885
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 NOTUM 1213/4885PRKCA 2421/4885PRKCD 1047/4885
US-20030203935-A1 Cyanobiphenyl derivatives F9, F12, F11 NOTUM 917/4885PRKCA 3767/4885PRKCD 3815/4885
US-20230159474-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS MRGPRX4, MRGPRX1, MRGPRX2 NOTUM 4318/4885PRKCA 2409/4885PRKCD 2383/4885
US-20240300907-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS MRGPRX4, MRGPRX1, MRGPRX2 NOTUM 4318/4885PRKCA 2409/4885PRKCD 2383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.